Ultragenyx Pharmaceutical Inc (RARE)

141.54 +5.29  +3.88% NASDAQ Feb 26, 20:00 USD
View Full Chart
Price Chart
View All RARE News

News

View All Events

Events

Date Type Description
05/06/2021 Earnings Ultragenyx Pharmaceutical Inc First Quarter Earnings Results for 2021
05/06/2021 Misc Ultragenyx Pharmaceutical Inc First Quarter Earnings Conference Call for 2021
02/12/2021 Misc Ultragenyx Pharmaceutical Inc Annual Report for 2020
02/11/2021 Earnings Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Result for 2020
02/11/2021 17:00 EST Misc Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 2020
10/27/2020 Earnings Ultragenyx Pharmaceutical Inc Third Quarter Earnings Result for 2020
10/27/2020 17:00 EDT Misc Ultragenyx Pharmaceutical Inc Third Quarter Earnings Conference Call for 2020
07/30/2020 17:00 EDT Misc Ultragenyx Pharmaceutical Inc Second Quarter Earnings Conference Call for 2020
07/30/2020 Earnings Ultragenyx Pharmaceutical Inc Second Quarter Earnings Result for 2020
06/26/2020 08:00 PDT Misc Ultragenyx Pharmaceutical Inc Annual General Meeting for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.ultragenyx.com
  • Investor Relations URL: http://ir.ultragenyx.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Blend
  • Next Earnings Release: May. 06, 2021
  • Last Earnings Release: Feb. 11, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.44%
KAUBX Federated Hermes Kaufmann B 3.22%
PTH Invesco DWA Healthcare Momentum ETF 2.40%
KLCKX Federated Hermes Kaufmann Large Cap R 2.26%
FKBSX Federated Hermes Kaufmann Small Cap B 2.04%
DCCRX Delaware Small Cap Core R 1.72%
THISX T. Rowe Price Health Sciences I 1.15%
FBIOX Fidelity® Select Biotechnology 1.10%
IWO iShares Russell 2000 Growth ETF 0.62%
VTWO Vanguard Russell 2000 ETF 0.35%
IWM iShares Russell 2000 ETF 0.31%
SCHA Schwab US Small-Cap ETF™ 0.22%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.